株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の細胞療法市場・臨床パイプラインの見通し

Global Cell Therapy Market & Clinical Pipeline Outlook 2022

発行 KuicK Research 商品コード 302594
出版日 ページ情報 英文 850 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界の細胞療法市場・臨床パイプラインの見通し Global Cell Therapy Market & Clinical Pipeline Outlook 2022
出版日: 2016年11月03日 ページ情報: 英文 850 Pages
概要

当レポートでは、世界の細胞療法市場について調査分析し、市場の概要、応用、機序、臨床パイプライン、上市製品、競合情勢などについて、体系的な情報を提供しています。

第1章 細胞療法の概要

第2章 細胞療法による治療の必要性

  • 幹細胞研究の台頭
  • 研究・治療用の幹細胞を使用するメリット

第3章 細胞療法における幹細胞の応用

  • 幹細胞能力で差別化
  • 幹細胞の由来

第4章 細胞療法の応用:治療領域別

  • 循環器疾患の細胞療法
  • 神経疾患の細胞療法
  • 炎症性疾患の細胞療法
  • 糖尿病の細胞療法
  • がんの細胞療法
  • がんの幹細胞療法

第5章 細胞療法の機序

  • 幹細胞療法の2大機序の原理
  • アルツハイマー病の作用機序

第6章 細胞療法の送達方法

  • 送達方法の概要
  • 直接
  • 間接

第7章 細胞療法による治療の機序

  • 同種幹細胞治療
  • 自己幹細胞治療

第8章 世界の細胞療法市場の概要

  • 現在の市場シナリオ
  • 細胞療法の世界市場の現在の動向
  • 世界の細胞療法の臨床パイプラインの概要

第9章 世界の細胞療法市場:地域別

  • 北米
  • 欧州
  • アジア
  • その他

第10章 世界の細胞療法市場力学

  • 好ましい市場パラメーター
  • 市場成長抑制要因

第11章 世界の細胞療法市場の将来見通し

第12章 世界の細胞療法の臨床パイプライン:企業別、適応別、相別

  • 段階不明
  • 研究
  • 前臨床
  • 臨床
  • 第0相
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相
  • 申請済み
  • 承認済み

第13章 上市済みの細胞療法の臨床分析:企業別、適応別

第14章 競合情勢

  • AlloCure
  • Arteriocyte Medical Systems
  • Athersys Inc.
  • Baxter Healthcare Corporation
  • Bone Therapeutics
  • Celgene Corporation
  • Cell Medica
  • Cellerant Therapeutics
  • FibrocellScinence
  • Forticell Bioscience
  • Genzyme Corporation
  • Green Cross Cell
  • Histogenics Corporation
  • InnovacellBiotechnologie AG
  • Intrexon Corporation
  • Intercytex
  • ISTO Technologies
  • Macrocure
  • Mesoblast
  • Molmed
  • Nuo Therapeutics Inc
  • OmniCyte
  • Opexa Therapeutics
  • Organogenesis
  • Pharmicell
  • TCA Cellular Therapy
  • Stem Cell Inc.
  • Teva Pharmaceuticals
  • Tigenix
  • Vericel Corporation

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

“Global Cell Therapy Market & Clinical Pipeline Outlook 2022” report published by Kuick Research gives comprehensive insight on the ongoing clinical and nonclinical trends in the global cell therapy market. Report analyzes the need and the application of cell therapy in multiple therapeutic areas along with the mechanism and delivery methods for cell therapy based treatment. The parameters impacting the growth of the market and the corresponding challenges limiting the commercialization of cell therapies are explained in the report.

The idea of cell therapy was in pharmaceutical industry for several decades but significant development was not made due to technological challenges. In recent years, cell therapy has gained widespread acceptance among physicians and patients due to its ability to treat various diseases. Several decades of research and development has allowed the investigators to come forth with solutions which can't be provided by conventional therapeutics. Theoretically, it could be used to cure plethora of diseases but underdeveloped technology has limited its usage to limited indications.

Several indications have been found to be curable with the help of cell therapies and indications are expected to be increased in near future. Cerebral disorders like Parkinson's disease and Alzheimer's disease are under investigation for treatment with the help of cell therapies. They are also being investigated for cardiovascular disease in which their aim is to restore normal heart functions. Investigators are also trying to find their safety and efficacy in treating various malignancies. On-going research is also aimed at curing metabolic disorder like diabetes mellitus type 1 in which patients tends to lack insulin production. Investigators are trying to restore the function of liver and kidney by supplementing them with modified cell of respective origins. Several clinical trials have been instigated across the globe in which their efficacy against different disease is being studies.

Cell therapy has potential in tissue development and regenerative medicine that could be used to make functional body parts. However, such researches are limited to laboratory levels and it will take very long time before successful instigation of clinical trials. Chances of their success are high as they have been able to develop the basic frame work in which conditions for growing different cells have been standardized. Now focus is on development of biocompatible matrix over which these cells could grow in predefined shape. Some materials have been found that are degraded from the system leaving behind the layer of cells in that shape. This shows that their approach is workable and someday they may be able to develop fully functional human organs.

Different individuals may respond to these therapies in different way and some of them develop hypertensive reaction during course of treatment. Some skeptics have raised concerns about safety of such treatment because more underlying principles have yet to be deciphered. For efficient treatment it is necessary to maintain their viability for elongated time and investigators are trying to figure out such methods. Cell therapy has significant commercialization potential but lots of work has yet to be done because its long-term effect on body is not known.

“Global Cell Therapy Market & Clinical Pipeline Outlook 2022” Highlights:

  • Introduction & Classification of Cell Therapies
  • Mechanism of Cell Therapy
  • Global Cell Therapy Market Analysis
  • Role of Stem Cells in Cell Therapy
  • Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
  • Global Cell Therapy Clinical Pipeline: 476
  • Marketed Cell Therapies: 20

Table of Contents

1. Introduction to Cell Therapy

2. Necessity for Cell Therapy Treatment

  • 2.1. Emergence of Stem Cell Research
  • 2.2. Benefits of Using the Stem Cell for Research & Treatment

3. Application of Stem Cells in Cell Therapy

  • 3.1. Stem Cells Ability to Differentiate
    • 3.1.1. Totipotent Stem Cells
    • 3.1.2. Pluripotent Stem Cells
    • 3.1.3. Multipotent Stem Cells
    • 3.1.4. Unipotent Stem Cells
  • 3.2. Origin of Stem Cells
    • 3.2.1. Embryonic Stem Cells
    • 3.2.2. Adult Stem Cells
    • 3.2.3. Induced Pluripotent Stem Cells (iPSCs)

4. Applications of Cell Therapy by Therapeutic Area

  • 4.1. Cell Therapy for Cardiovascular Diseases
  • 4.2. Cell Therapy for Neurological Disorders
  • 4.3. Cell Therapy for Inflammatory Diseases
  • 4.4. Cell Therapy for Diabetes
  • 4.5. Cell Therapy for Cancer
  • 4.6. Cancer Stem Cells Therapy
    • 4.6.1. Therapies of Targeting the Cancer Stem Cells
      • 4.6.1.1. Targeting the Surface Markers
      • 4.6.1.2. Targeting the Signal Cascades
      • 4.6.1.3. Targeting the Microenvironment

5. Mechanism of Cell Therapy

  • 5.1. Two Major Mechanism Principles of Stem Cell Based Therapy
    • 5.1.1. Interaction of Modified Cells with Body
      • 5.1.1.1. Stem Cell Paracrine Actions in Heart Repair
    • 5.1.2. Mechanism of Regenerative Cell Therapy
      • 5.1.2.1. Regenerative Medicine Therapies for Diabetes
  • 5.2. Mechanism of Action in Alzheimer's Diseases

6. Delivery Method of Cell Based Therapy

  • 6.1. Outline to Delivery Methods
  • 6.2. Direct Delivery Methods
    • 6.2.1. Intravascular Infusions
    • 6.2.2. Trans- Mucosal Delivery
  • 6.3. Indirect Delivery of the Cells by Using the Carrier
    • 6.3.1. Natural Biomaterials
    • 6.3.2. Synthetic Biomaterials

7. Mechanism of Cell Therapy Treatment

  • 7.1. Allogeneic Stem Cell Therapy
  • 7.2. Autologous Stem Cell Therapy

8. Global Cell Therapy Market Overview

  • 8.1. Current Market Scenario
  • 8.2. Current Trends of Cell Therapy in Global Market
  • 8.3. Global Cell Therapies Clinical Pipeline Overview

9. Global Cell Therapy Market by Region

  • 9.1. North America
  • 9.2. Europe
  • 9.3. Asia
  • 9.4. Rest of the World

10. Global Cell Therapy Market Dynamics

  • 10.1. Favorable Market Parameters
  • 10.2. Factors Limiting Market Growth

11. Global Cell Therapy Market Future Prospect

12. Global Cell Therapies Clinical Pipeline by Company, Indication & Phase

  • 12.1. Unknown
  • 12.2. Research
  • 12.3. Preclinical
  • 12.4. Clinical
  • 12.5. Phase-0
  • 12.6. Phase-I
  • 12.7. Phase-I/II
  • 12.8. Phase-II
  • 12.9. Phase-II/III
  • 12.10. Phase-III
  • 12.11. Preregistration
  • 12.12. Registered

13. Marketed Cell Therapies Clinical Insight by Company & Indication

  • 13.1. T-Lymphocyte Cell Therapy (Immuncell-LC)
  • 13.2. Muscle-Derived Autologous Stem Cell Therapy (MyoCell & MyoCell SDF-1)
  • 13.3. Azficel-T (Laviv)
  • 13.4. Sipuleucel-T (Provenge)
  • 13.5. Placental Derived Mesenchymal Stem Cell Therapy - Osiris Therapeutics
  • 13.6. Remestemcel-L (Prochymal & TEMCELL HS Inj.)
  • 13.7. Autologous Mesenchymal Stem Cell Therapy - Pharmicell
  • 13.8. Autologous Cultured Chondrocytes (MACI)
  • 13.9. Mesenchymal Stem Cell Therapy for Cartilage Repair (Cartistem)
  • 13.10. Leukocyte Cell Therapy (CureXcell)
  • 13.11. Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
  • 13.12. Allogeneic Cultured Keratinocytes and Fibroblasts (Gintuit)
  • 13.13. Autologous Cultured Chondrocyte Implant (Carticel)
  • 13.14. Autologous Cultured Chondrocytes (CHONDRON)
  • 13.15. Autologous Chondrocytes (BioCart & BioCartII)
  • 13.16. Amniotic Cell Therapy (NuCel)
  • 13.17. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
  • 13.18. Autologous Cultured Chondrocytes (Chondrotransplant DISC)
  • 13.19. Autologous Cultured Myoblasts and Fibroblasts (Urocell)
  • 13.20. Human Skin Replacement (CellSpray & CellSpray XP)

14. Competitive Landscape

  • 14.1. AlloCure
  • 14.2. Arteriocyte Medical Systems
  • 14.3. Athersys Inc.
  • 14.4. Baxter Healthcare Corporation
  • 14.5. Bone Therapeutics
  • 14.6. Celgene Corporation
  • 14.7. Cell Medica
  • 14.8. Cellerant Therapeutics
  • 14.9. FibrocellScinence
  • 14.10. Forticell Bioscience
  • 14.11. Genzyme Corporation
  • 14.12. Green Cross Cell
  • 14.13. Histogenics Corporation
  • 14.14. InnovacellBiotechnologie AG
  • 14.15. Intrexon Corporation
  • 14.16. Intercytex
  • 14.17. ISTO Technologies
  • 14.18. Macrocure
  • 14.19. Mesoblast
  • 14.20. Molmed
  • 14.21. Nuo Therapeutics Inc
  • 14.22. OmniCyte
  • 14.23. Opexa Therapeutics
  • 14.24. Organogenesis
  • 14.25. Pharmicell
  • 14.26. TCA Cellular Therapy
  • 14.27. Stem Cell Inc.
  • 14.28. Teva Pharmaceuticals
  • 14.29. Tigenix
  • 14.30. Vericel Corporation

List of Figures

  • Figure 1-1: Properties of the Stem Cell
  • Figure 1-2: Outline to the Cell Therapy Components
  • Figure 2-1: History of Stem Cell Research
  • Figure 2-2: Promise of the Stem Cell Research
  • Figure 3-1: Type of Stem Cells on the Basis of Ability to Differentiate
  • Figure 3-2: Type of Stem Cells on the Basis of Origin
  • Figure 4-1: Stem Cell Therapy for Cardiovascular Diseases
  • Figure 4-2: Cell Therapy in Parkinson's disease
  • Figure 4-3: Cell Therapy for Inflammatory Disorder
  • Figure 4-4: Cell Therapy for Diabetes
  • Figure 4-5: Strategies which are adopted for targeting the Cancer Stem Cells
  • Figure 5-1: Mechanism of Paracrine Signaling
  • Figure 5-2: Demonstration of the Endocrine Signaling
  • Figure 5-3: Illustration of the Autocrine Signaling
  • Figure 5-4: Paracrine Signaling in Heart Repair
  • Figure 5-5: Treatment of Alzheimer's Diseases
  • Figure 7-1: Allogeneic Stem Cell Therapy
  • Figure 7-2: Steps of Autologous Stem Cell Therapy
  • Figure 8-1: Global Cell Therapy Market (US$ Billion), 2012-2022
  • Figure 8-2: Global - Cell Therapies Clinical Pipeline by Phase (%), 2016 till 2022
  • Figure 8-3: Global - Cell Therapies Clinical Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 8-4: Global - Cell Therapies Clinical Pipeline by Phase (%), 2016 till 2022
  • Figure 8-5: Global - Cell Therapies Clinical Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 10-1: Favorable Market Drivers
  • Figure 10-2: Factors Limiting the Cell Therapy Market
  • Figure 11-1: Future Projections of Stem Cell Therapy
  • Figure 14-1: Arteriocyte Medical Systems Clinical Pipeline
  • Figure 14-2: Bone Therapeutics Clinical Pipeline
  • Figure 14-3: Celgene Clinical Pipeline
  • Figure 14-4: Cellerant Therapeutics Clinical Pipeline
  • Figure 14-5: Fibrocell Science Clinical Pipeline
  • Figure 14-6: Genzyme Clinical Pipeline
  • Figure 14-7: Intrexon Clinical Pipeline
  • Figure 14-8: ISTO Clinical Pipeline
  • Figure 14-9: Mesoblast Clinical Pipeline
  • Figure 14-10: Molmed Clinical Pipeline
  • Figure 14-11: Pharmicell Clinical Pipeline
  • Figure 14-12: Tigenix Clinical Pipeline
  • Figure 14-13: Vericel Corporation Clinical Pipeline

List of Tables

  • Table 7-1: Difference between Embryonic, Adult & Induced Stem Cells
  • Table 8-1: List of the Blockbuster Drugs
  • Table 9-1: Cell Therapy Market Growth
Back to Top